Search results
Added:
1 month ago
Source:
CFR Journal Radcliffe Cardiology
A prespecified, secondary analysis of the MAPLE-HCM trial has shown that aficamten monotherapy provides superior and rapid benefits across multiple domains of disease burden compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).¹ Aficamten is a next-in-class cardiac myosin inhibitor (CMI) designed to reduce myocardial hypercontractility by decreasing…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
An artificial intelligence (AI)-augmented clinical programme may significantly improve the detection of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is frequently underdiagnosed, according to the results of a new nonrandomized clinical trial.¹ The study evaluated an AI model, ATTRACTnet, in a real-world setting to identify patients missed by usual care.The ATTRACTnet model was…
View more
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added:
6 months ago
Source:
Radcliffe Cardiology
News
Added:
8 months ago
Source:
Radcliffe Cardiology
A new whitepaper from the International Cardio-Oncology Society (ICOS) CORE working group outlines a critical roadmap for advancing the cardiovascular care of cancer survivors. Published in the European Heart Journal, the paper reviews the current evidence for cardio-oncology rehabilitation and exercise (CORE) programmes and sets new standards for future research to address significant knowledge…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
New data from the SEQUOIA-HCM trial suggests that the cardiac myosin inhibitor aficamten provides significant clinical benefits for patients with obstructive hypertrophic cardiomyopathy (oHCM) and mild symptoms, with an efficacy and safety profile comparable to that seen in patients with more advanced symptoms.¹Aficamten is a novel, selective cardiac myosin inhibitor that works by reducing the…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
With global temperatures rising and heatwaves becoming more frequent and intense, the impact on public health is a growing concern. A new scientific statement from the European Society of Cardiology (ESC) and several of its constituent bodies highlights the significant risk that extreme heat poses to cardiovascular health, particularly for the elderly and individuals with pre-existing…
View more
Added:
8 months ago
Source:
Radcliffe Cardiology
A large-scale, nationwide study from South Korea suggests that vaccination with the live zoster vaccine is associated with a significantly lower risk of various cardiovascular (CV) events in adults aged 50 and older. The findings indicate a protective association that persists for up to 8 years post-vaccination.¹This population-based cohort study analysed data from over 2.2 million individuals…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
For patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the net effect of right ventricular pacing (RVP) has been variable. A new trial suggests that personalising the therapy by electromechanically optimising the atrio-ventricular delay (AVD) can provide a net benefit for symptoms and exercise capacity.¹Right ventricular pacing can reduce the left ventricular outflow tract…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
Cardiovascular magnetic resonance (CMR) with extracellular volume (ECV) mapping can effectively track changes in cardiac amyloid burden in transthyretin amyloid cardiomyopathy (ATTR-CM) and is independently associated with patient outcomes, according to a new prospective study.¹This single-centre prospective study included 189 patients with ATTR-CM. The cohort was divided into an untreated group …
View more